Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1902 4
1903 1
1927 1
1933 2
1938 1
1943 1
1946 2
1949 5
1950 3
1951 5
1952 2
1953 5
1954 5
1955 5
1956 1
1960 2
1962 2
1963 1
1964 3
1965 3
1966 3
1967 1
1968 2
1969 2
1970 7
1971 6
1972 9
1973 11
1974 5
1975 6
1976 11
1977 8
1978 1
1979 3
1980 3
1981 6
1982 8
1983 3
1984 7
1985 4
1986 10
1987 9
1988 12
1989 10
1990 8
1991 11
1992 7
1993 9
1994 14
1995 11
1996 4
1997 6
1998 10
1999 12
2000 37
2001 28
2002 20
2003 20
2004 15
2005 17
2006 18
2007 20
2008 17
2009 21
2010 16
2011 29
2012 11
2013 25
2014 18
2015 28
2016 20
2017 34
2018 40
2019 45
2020 29
2021 21
Text availability
Article attribute
Article type
Publication date

Search Results

772 results
Results by year
Filters applied: . Clear all
Page 1
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. Among authors: ferguson gt. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
Goals of COPD treatment: Focus on symptoms and exacerbations.
Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Vogelmeier CF, et al. Among authors: ferguson gt. Respir Med. 2020 May;166:105938. doi: 10.1016/j.rmed.2020.105938. Epub 2020 Mar 21. Respir Med. 2020. PMID: 32250871 Review.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Ferguson GT, et al. Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. Lancet Respir Med. 2018. PMID: 30232048 Clinical Trial.
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P. Rabe KF, et al. Among authors: ferguson gt. Respir Med. 2019 Oct-Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22. Respir Med. 2019. PMID: 31605923 Free article. Clinical Trial.
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. FitzGerald JM, et al. Among authors: ferguson gt. Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5. Lancet. 2016. PMID: 27609406 Clinical Trial.
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators. Busse WW, et al. Among authors: ferguson gt. Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Lancet Respir Med. 2019. PMID: 30416083 Clinical Trial.
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ. Maltais F, et al. Among authors: ferguson gt. Adv Ther. 2019 Sep;36(9):2434-2449. doi: 10.1007/s12325-019-01015-3. Epub 2019 Jul 2. Adv Ther. 2019. PMID: 31267366 Clinical Trial.
772 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page